These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38713076)

  • 21. Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies.
    Raffaelli B; Terhart M; Fitzek MP; Lange KS; Mecklenburg J; Overeem LH; Siebert A; Storch E; Reuter U
    Pharmaceutics; 2023 Jan; 15(1):. PubMed ID: 36678920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. One-Time Use of Galcanezumab or Fremanezumab for Migraine Prevention.
    Katsuki M; Kashiwagi K; Kawamura S; Tachikawa S; Koh A
    Cureus; 2023 Jan; 15(1):e34180. PubMed ID: 36843788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment patterns of galcanezumab versus standard of care preventive migraine medications over 24 months: a US retrospective claims study.
    Varnado OJ; Vu M; Buysman EK; Kim G; Allenback G; Hoyt M; Trenz H; Cao F; Viktrup L
    Curr Med Res Opin; 2024 Apr; 40(4):635-646. PubMed ID: 38334320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis.
    Lambru G; Caponnetto V; Hill B; Ratti S; Sacco S; Murphy M; Briscoe J; Andreou AP
    Neurotherapeutics; 2023 Sep; 20(5):1284-1293. PubMed ID: 37430146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of anti-CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy.
    Hyeraci G; Paoletti O; Iannone LF; Gini R; De Cesaris F; Geppetti P; Roberto G
    Headache; 2023; 63(10):1391-1402. PubMed ID: 37830925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
    Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
    Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study.
    Grazzi L; Giossi R; Montisano DA; Canella M; Marcosano M; Altamura C; Vernieri F
    J Headache Pain; 2024 Feb; 25(1):14. PubMed ID: 38308209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy.
    Lee MJ; Al-Karagholi MA; Reuter U
    Cephalalgia; 2023 Feb; 43(2):3331024221146315. PubMed ID: 36759320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
    Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
    CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Network meta-analysis on efficacy and safety of different anti-CGRP monoclonal antibody regimens for prophylaxis and treatment of episodic migraine.
    Shi M; Guo J; Li Z; Sun H; Yang X; Yang D; Zhao H
    Neurol Res; 2021 Nov; 43(11):932-949. PubMed ID: 34281473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Study of the Efficacy of Anti-CGRP mAbs on Migraineurs: Analysis of the First Year of Therapy, 1-Month Suspension Period, and Reprisal.
    Tereshko Y; Dal Bello S; Pez S; Belgrado E; Lettieri C; Ercole BH; Cellante G; Del Regno C; Sportelli G; Ermanis G; Versace S; Merlino G; Gigli GL; Valente M
    J Clin Med; 2023 Nov; 12(23):. PubMed ID: 38068383
    [No Abstract]   [Full Text] [Related]  

  • 32. Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(-receptor) antibodies.
    Terhart M; Mecklenburg J; Neeb L; Overeem LH; Siebert A; Steinicke M; Raffaelli B; Reuter U
    J Headache Pain; 2021 Dec; 22(1):158. PubMed ID: 34972502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switching between anti-calcitonin gene-related peptide monoclonal antibodies: A comparison of monthly and quarterly dosing.
    Ihara K; Ohtani S; Watanabe N; Takahashi N; Miyazaki N; Takemura R; Hori S; Nakahara J; Takizawa T
    J Neurol Sci; 2023 Oct; 453():120811. PubMed ID: 37757639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients.
    Curone M; Tullo V; Didier HA; Bussone G
    Neurol Sci; 2022 Sep; 43(9):5759-5761. PubMed ID: 35836032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.
    Alex A; Vaughn C; Rayhill M
    Headache; 2020 Nov; 60(10):2454-2462. PubMed ID: 32969035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review.
    Aditya S; Rattan A
    Saudi J Med Med Sci; 2023; 11(1):11-18. PubMed ID: 36909005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case report of a chronic migraine patient treated with three different anti-CGRP monoclonal antibodies: which parameters better represent the efficacy?
    Uzun S; Frejvall U; Özkaya-Sahin G; Sahin G
    Front Neurol; 2023; 14():1176816. PubMed ID: 37213912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
    Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
    CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study.
    Ihara K; Ohtani S; Watanabe N; Takahashi N; Miyazaki N; Ishizuchi K; Hori S; Takemura R; Nakahara J; Takizawa T
    J Headache Pain; 2023 Mar; 24(1):23. PubMed ID: 36890436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.